Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
16.76 USD | -0.65% | +7.88% | +13.03% |
Apr. 18 | Alx Oncology Holdings Insider Sold Shares Worth $710,195, According to a Recent SEC Filing | MT |
Apr. 10 | ALX Oncology Reports Positive Data From Ongoing Phase 1/2 Trial of Evorpacept | MT |
Business Summary
Number of employees: 72
Managers
Managers | Title | Age | Since |
---|---|---|---|
Jaume Pons
FOU | Founder | 58 | 15-03-31 |
Jason Lettmann
CEO | Chief Executive Officer | 46 | 20-03-31 |
Peter García
DFI | Director of Finance/CFO | 62 | 19-12-31 |
Chief Tech/Sci/R&D Officer | - | 21-10-31 | |
Sophia Randolph
CTO | Chief Tech/Sci/R&D Officer | 56 | 16-05-31 |
Michael Chang
COO | Chief Operating Officer | - | 15-02-28 |
Shelly Pinto
AUD | Comptroller/Controller/Auditor | 48 | 21-05-02 |
Hong I. Wan
PRN | Corporate Officer/Principal | - | 15-03-31 |
Hank Stern
PRN | Corporate Officer/Principal | - | 14-12-31 |
Chris Byrd
LAW | General Counsel | - | 22-04-30 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
J. Garland
BRD | Director/Board Member | 55 | 22-11-27 |
Corey Goodman
CHM | Chairman | 72 | 15-02-28 |
Jack Nielsen
BRD | Director/Board Member | 60 | 20-03-31 |
Jason Lettmann
CEO | Chief Executive Officer | 46 | 20-03-31 |
Rekha Hemrajani
BRD | Director/Board Member | 54 | 20-03-31 |
Jaume Pons
FOU | Founder | 58 | 15-03-31 |
Sophia Randolph
CTO | Chief Tech/Sci/R&D Officer | 56 | 16-05-31 |
Itziar Canamasas
BRD | Director/Board Member | 50 | 22-04-10 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 50,152,082 | 39,460,945 ( 78.68 %) | 0 | 78.68 % |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+13.03% | 852M | |
-1.83% | 103B | |
+0.54% | 95.71B | |
+1.69% | 22.02B | |
-17.36% | 20.9B | |
-9.30% | 17.85B | |
-41.01% | 16.21B | |
-15.03% | 15.52B | |
+3.50% | 13.86B | |
+35.24% | 12.04B |
- Stock Market
- Equities
- ALXO Stock
- Company ALX Oncology Holdings Inc.